Onxeo Seeks Partner For Its Expanding Oncology Pipeline

Onxeo, a biotech company developing drugs for orphan oncology indications, plans to secure financial backing from a pharma partner for its lead product Livatag based on impending Phase III results, CEO Judith Greciet told Scrip in an interview.